MAP3K11

Across TCGA pan-cancer cohorts, MAP3K11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP3K11 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAP3K11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP3K11 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where MAP3K11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.933	0.444	<.001	45	view →
LUAD	OS	Tertile	All	0.943	0.523	.002	24	view →
LSCC	DFS	Tertile	II,III,IV	0.355	1.000	.006	9	view →
HNSC	OS	Median	IV	0.876	0.601	.011	6	view →
PDAC	DFS	Tertile	II,III,IV	0.621	0.260	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP3K11–CCRCC (DFS)

Open the CCRCC breakdown →